The size of the Asia Pacific In-vitro fertilization market is expected to be worth USD 1.02 billion by 2025 from USD 0.44 billion in 2022, growing at a CAGR of 18.4% from 2022 to 2027.
The IVF market in the APAC region is estimated to exhibit significant growth during the forecast period, owing to an increase in the incidence of infertility, hormonal insufficiency treatments, the trend of late pregnancy, advancement in technology related to IVF and an increase in disposable income in the region. It has been recorded that the fertility rates are decreased in Asia-Pacific countries such as Japan, Singapore, India, Taiwan, South Korea, China, and Hong Kong. Lifestyle changes, including the preference for a stable life, increasing age at first birth, the shift from rural to urban societies, and declining marriage rates, among others, contribute to the decrease in the total fertility rate in these countries. According to the Australian Bureau of statistics 2015, In Australia, the average age of new mothers fell from 27.9 years in 2003 to 28.8 years in 2013. Several countries, such as Vietnam, Cambodia, and the Philippines, have fertility rates of 2 births per woman, which is lower than the average rate of 2.5 births per woman.
In older women over 40 years, the eggs produced by the reproductive system are not fully formed for the fertilization process, or the eggs are produced in a lesser number. This can lead to several risks of genetic disorders in the egg and complications in the pregnancy such as miscarriage, pre-term babies, stillbirths, and other medical complications. Hence, an increase in the trend of late pregnancies among women is expected to drive the growth of the APAC IVF market in the years to come.
The cost of IVF treatment is subject to various reimbursement policies in different regions. Unfortunately, insurance companies generally do not cover the cost of infertility treatments. Infertility is not considered a severe health problem; therefore, it is not covered by general insurance. Thus, the high price of assisted reproduction techniques (ART) to treat infertility and the lack of awareness of treatment options are holding back the growth of this market.
This research report on the Asia Pacific In-vitro fertilization market has been segmented and sub-segmented into the following categories:
By Reagents and Media:
By Instruments:
By Technology:
By End Users:
By Country: I
In 2020, the Chinese market held the largest share in the studied market. The market growth is due to continuous innovations to improve the success rate of IVF treatment, large population base, government initiatives, low costs of IVF treatments, increasing numbers of infertile disorders such as endometriosis, PCOS cancer, etc. Every year around the world, thousands of in vitro fertilization cycles are performed due to a limited success rate. This will drive the market sales during the analysis period.
The Indian market is expected to post the highest CAGR of 13.9% during the forecast period, owing to the availability of skilled professionals, increasing procedures per year, and technological advancements in the region. Other regions such as Japan, Vietnam, Australia, and South Korea are also expected to have reasonable growth rates in the years to come. The rapid growth of the senior population has been of great concern to the local government in the Asia-Pacific region. These regions are focused on increasing their fertility rates to maintain the balance between neonatal and geriatric populations. Indonesia had a fertility rate of 2.3 and an aging population of around 5.2% of the total population in 2016. In addition to low-cost treatment, high-quality treatments, lesser strict fertility treatment laws also encourage fertility tourism in emerging Asian countries such as India, the Philippines, and Thailand. Many governments are providing better maternity benefits to increase the birth rate and improve medical facilities for IVF treatment, and these are acting as potential drivers contributing to mass adoption of IVF treatment in Asia-Pacific countries.
KEY MARKET PLAYERS:
Companies playing a prominent role in the APAC In-Vitro Fertilization Market profiled in this report are CooperSurgical, Inc. (U.S.), Vitrolife AB (Sweden), Cook Medical, Inc. (U.S.), Irvine Scientific (U.S.), Thermo Fisher Scientific, Inc. (U.S.), EMD Serono, Inc. (U.S.), Genea Limited (Australia), ESCO Micro Pte. Limited (Singapore), IVFtech ApS (Denmark), and The Baker Company, Inc. (U.S.).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Introduction
5.2 Reagents and Media
5.2.1 Introduction
5.2.2 Embryo Culture Media
5.2.3 Cryopreservation Media 5.2.2.1 Autologous Cell-Based Products
5.2.4 Sperm Processing Media 5.2.2.2 Allogeneic Cell-Based Products
5.2.5 Ovum Processing Media
5.3 Instruments
5.3.1 Introduction
5.3.2 Imaging Systems
5.3.3 Sperm Separation Systems
5.3.4 Ovum Aspiration Pumps
5.3.5 Incubators
5.3.6 Micromanipulator Systems
5.3.7 Cryosystems
5.3.8 Other Instruments (Gas Analyzers, Laser Systems, Accessories)
5.4 Technology
5.3.1 Introduction
5.3.2 Intra-Cytoplasmic Sperm Injection (ICSI)
5.3.3 Pre-Implantation Genetic Diagnosis (PGD)
5.3.4 Frozen Embryo Transfer/Replacement (FET/FER)
5.3.5 Other Technologies
5.5 End Users
5.4.1 Introduction
5.4.2 Fertility and Surgical Centers
5.4.3 Hospitals and Research Laboratories
5.4.4 Cryobanks
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 CooperSurgical, Inc. (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Cook Medical, Inc. (U.S.)
8.3 Irvine Scientific (U.S.)
8.4 Vitrolife AB (Sweden)
8.5 Thermo Fisher Scientific, Inc. (U.S.)
8.6 EMD Serono, Inc. (U.S.)
8.7 Genea Limited (Australia)
8.8 ESCO Micro Pte. Limited (Singapore)
8.9 IVFtech ApS (Denmark)
8.10 The Baker Company, Inc. (U.S.)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
